Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
31 results
Search Results
Item Long Term Effects Of Eplerenone Treatment In Children With Chronic Allograft Dysfunction(2022) Baskin, Esra; Gulleroglu, Kaan; Yilmaz, Aysun Caltik; Ozdemir, B. Handan; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0003-0774-4419; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; F-3294-2013; AAD-1877-2021; AAC-5566-2019; AAJ-8097-2021Item Assessment Of Long-Term Outcomes Of Pediatric Liver Transplant Recipients(2022) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Ozcay, Figen; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; AAC-5566-2019; AAJ-8097-2021Item Long Term Outcomes Of Kidney Transplant In Pediatric Recipients(2022) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Baskin, Esra; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; AAC-5566-2019; AAJ-8097-2021Item The Reliability And Validity Study Of Pediatric Transplant Rating Instrument In Turkish Renal Transplant Patients(2022) Taner, Hande Ayraler; Sari, Burcu Akin; Baskin, Esra; Kazanci, Nafia Ozlem; Karakaya, Jale; Gulleroglu, Kaan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3462-7632; F-3294-2013; AAC-5566-2019; AAJ-8097-2021Item Liver Transplant Experiences For The Budd-Chiarı Syndrome At Baskent University Transplant Centers(2021) Karakaya, Emre; Akdur, Aydincan; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Etik, Digdem Ozer; Boyvat, Fatih; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; F-4230-2011; AAA-3068-2021; AAJ-8097-2021Item Clinical Outcomes Of Liver Transplantation For Patients Over 60 Years Old; A Single Center Experience(2021) Akdur, Aydincan; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Karakayali, Feza; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; AAC-5566-2019; AAA-3068-2021; AAJ-8097-2021Item Urinary Tract Infections And Long Term Outcomes After Pediatiıc Renal Transplantation(2021) Baskin, Esra; Akdur, Aydincan; Gulleroglu, Kaan; Karakayali, Feza; Soy, Ebru H. Ayvazoglu; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; 0000-0003-1434-3824; AAC-5566-2019; AAA-3068-2021; AAJ-8097-2021; AAJ-8833-2021Item Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant(2020) Rahatli, Samed; Soy, Ebru H. Ayvazoglu; Oguz, Arzu; Altundag, Ozden; Moray, Gokhan; Haberal, Mehmet; 0000-0003-0197-6622; 0000-0002-3462-7632; 0000-0003-2498-7287; 0000-0003-3163-7429; 0000-0001-6512-6534; 0000-0002-0993-9917; 32279656; W-9219-2019; AAJ-8097-2021; AAE-1041-2021; AAJ-3047-2021; W-8004-2019; AAC-5566-2019Objectives: Hepatocellular carcinoma remains a major health problem with increased rates of mortality. The curative treatment options are resection or liver transplant. Because the Milan criteria are restrictive for candidates, they have been expanded into alternative sets of criteria. We aimed to evaluate our indications for liver transplant and their results for hepatocellular carcinoma. Materials and Methods: Between December 1988 and January 2020, we performed 652 liver transplant procedures (443 living donors, 209 deceased donors) at Baskent University (Ankara, Turkey). At Baskent University, we developed liver transplant criteria for patients with hepatocellular carcinoma. For our criteria, liver transplant for hepatocellular carcinoma was performed in patients without major vascular invasion and distant metastasis. Clinical data on cancer demographics, recurrence patterns, and survival outcomes were evaluated retrospectively. Results: Of 652 total patients, 49 adult patients (8%) with diagnosis of hepatocellular carcinoma were included in this study. Median age was 55 years. Hepatocellular carcinoma recurrence after liver transplant was detected in 13 patients. Median overall survival was 64.3 months for all study patients; however, median survival was significantly lower in patients who had recurrence (126.3 vs 43.4 mo for nonrecurrent vs recurrent groups; P = .024). In the expanded criteria group (n = 25), 7 patients (28%) had hepatocellular carcinoma recurrence during follow-up, whereas this ratio was 25% (6/24 patients) in the Milan criteria group, with median time to recurrence of 12.6 versus 11.7 months, respectively (not significantly different). Conclusions: Multidisciplinary treatment modalities, including surgery, interventional radiology techniques, and medical treatments, will probably lead to prolonged survival in patients with hepatocellular carcinoma. According to our center's expanded criteria, recurrence rates and time to recurrence were similar to those shown with the Milan group. We showed that Milan criteria can be safely expanded with promising results even in patients beyond Milan criteria.Item Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience(2020) Akdur, Aydincan; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Alshalabi, Omar; Kirnap, Mahir; Arslan, Hande; Ulubay, Gaye; Hekimoglu, Koray; Moray, Gokhan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-0805-0841; 0000-0002-3462-7632; 0000-0003-2478-9985; 0000-0003-2498-7287; 0000-0002-8726-3369; 0000-0002-4879-7974; 32519617; AAC-5566-2019; AAD-9097-2021; AAJ-8097-2021; AAB-5064-2021; AAE-1041-2021; AAA-3068-2021; AAD-5466-2021Objectives: The novel 2019 coronavirus (COVID-19) was first described in December 2019 in Wuhan, China and subsequently announced as a pandemic on March 12, 2020. In several studies, solid-organ transplant recipients were reported to have higher risk for COVID-19. Here, we aimed to determine the frequency of COVID-19 in our kidney and liver transplant patients. Materials and Methods: Our study included 583 transplant patients who were admitted to our outpatient transplant clinics and emergency departments between March 1 and May 1, 2020. Seventy-four of them were liver transplant recipients (46 male, 28 female, of which 14 were pediatric and 60 were adult patients) and 509 of them were kidney transplant recipients (347 male, 162 female, of which 16 were pediatric and 493 were adult patients). We retrospectively evaluated demographic characteristics, currently used immunosuppressant treatment, present complaints, treatment and diagnosis of comorbid diseases, and results of COVID-19 tests. Results: Of 583 transplant recipients, 538 were seen in our outpatient transplant clinics and 45 were seen in our emergency departments. Of these, 18 patients who had had cough and fever were evaluated by respiratory clinic doctors, and nasopharyngeal swab samples were taken. One kidney transplant recipient had a positive COVID-19 test; he was followed with home isolation. He received treatment with hydroxychloroquine (400 mg/day). The other 17 patients had negative tests. There were no mortalities due to COVID-19. Conclusions: Transplant patients also got affected during the COVID-19 pandemic. According to the data of our centers, this effect is not much more different from the normal population. We recommend that transplant recipients should be warned in terms of personal hygiene and should be closely monitored by organ transplant centers. If there is an indication for hospitalization, they should be followed in an isolated unit, with no aggressive changes made to immunosuppressive doses unless necessaryItem Liver and Kidney Transplant During a 6-Month Period in the COVID-19 Pandemic: A Single-Center Experience(2020) Akdur, Aydincan; Karakaya, Emre; Soy, Ebru H. Ayvazoglu; Karakayali, Feza Yarbug; Yildirim, Sedat; Torgay, Adnan; Sayin, Cihat Burak; Coskun, Mehmet; Moray, Gokhan; Haberal, Mehmet; 0000-0002-1874-947X; 0000-0002-6829-3300; 0000-0002-8726-3369; 0000-0002-0993-9917; 0000-0002-3462-7632; 0000-0002-5735-4315; 0000-0002-4879-7974; 0000-0003-2498-7287; 0000-0001-5630-022X; 33143601; AAB-3888-2021; AAJ-5221-2021; AAA-3068-2021; AAC-5566-2019; AAJ-8097-2021; AAF-4610-2019; AAD-5466-2021; AAE-1041-2021; AAM-4120-2021Objectives: With the declaration of COVID-19 as a pandemic, many studies have indicated that elective surgeries should be postponed. However, post-ponement of transplants may cause diseases to get worse and increase the number in wait lists. We believe that, with precautions, transplant does not pose a risk during pandemic. Here, we aimed to evaluate our transplant results, which we safely performed during a 6-month pandemic period. Materials and Methods: Until September 2020, 3140 kidney and 667 liver transplants have been performed in our centers. We evaluated 38 kidney transplants and 9 liver transplants procedures performed during the pandemic (March 1 to September 2, 2020). Recipient and donor candidates were screened for COVID-19 with polymerase chain reaction and thoracic computed tomography. All recipients had routine immunosuppressive protocol. During hospitalization at our COVID-19-free transplant facility, we restricted the interactions during multidisciplinary rounds. Results: During the pandemic, 38 kidney transplants with an average length of hospital stay of 8.1 days were performed. Mean serum creatinine values of recipients were 0.91, 0.86, and 0.74 mg/dL on postoperative days 7, 30, and 90, respectively. During the pandemic, 9 living donor liver transplants (1 adult, 8 pediatric) were performed with an average length of hospital stay of 17.1 days. Mean serum total bilirubin levels were 0.9, 0.5, and 0.4 mg/dL on postoperative days 7, 30, and 90, respectively. Mean serum aspartate aminotransferase levels were 38.1, 28.3, and 22.3 U/L on postoperative days 7, 30, and 90, respectively. All recipients and donors were successfully discharged. Only 1 liver recipient died (on day 55 after discharge as a result of oxalosis-induced heart failure). Conclusions: According to our results, when precautions are taken, transplant does not pose a risk to patients during the pandemic period. We attribute the safety and success shown to our newly developed protocol in response to the COVID-19 pandemic.